<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04592081</url>
  </required_header>
  <id_info>
    <org_study_id>The Assil Study</org_study_id>
    <nct_id>NCT04592081</nct_id>
  </id_info>
  <brief_title>Dextenza Within Upper Lid Canaliculus Compared With Lower Lid Canaliculus Following Bilateral Cataract Extraction Surgery With PCIOL.</brief_title>
  <official_title>A Randomized Controlled Clinical Trial aSsessing the Efficacy of DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert When Placed Within the Upper Eye Lid Canaliculus in Comparison to the Lower Lid Canaliculus Following Bilateral Cataract Extraction Surgery With Posterior Chamber Intraocular Lens Implant (CE/PCIOL).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kerry Assil, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assil Eye Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessing DEXTENZA efficacy when placed within the upper eyelid canaliculus as opposed to the&#xD;
      lower eyelid canaliculus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized controlled clinical trial assessing the efficacy of DEXTENZA, sustained release&#xD;
      dexamethasone 0.4 mg insert when placed within the upper eye lid canaliculus in comparison to&#xD;
      the lower lid canaliculus following bilateral cataract extraction surgery with posterior&#xD;
      chamber intraocular lens implant (CE/PCIOL).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">March 11, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All patients will receive: First eye randomized for either lower lid (control eye) or upper lid (study eye) insertion and the contralateral eye receiving the opposite site insertion in the OR following CE/PCIOL</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative inflammation scores</measure>
    <time_frame>Assessed on Days 1, 7, 30 for change</time_frame>
    <description>As measured on a scale of 0-4: absence of cell to be defined as a grade of 0-0.5, absence of flare to be defined as a grade of 0-1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-op pain scores</measure>
    <time_frame>Assessed on Days 1, 7, 30 for change</time_frame>
    <description>As measured on a scale from 0-10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ease of Insertion (successful implantation)</measure>
    <time_frame>Assessed on Day 0 (Day of Insertion)</time_frame>
    <description>As measured by Physician Ease of Use Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure</measure>
    <time_frame>Assessed on Days 1, 7, 30, 90 for change</time_frame>
    <description>As measured by Goldmann Applanation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Outcome</measure>
    <time_frame>Assessed at all time points;comparison of Day 30 vs Day 90</time_frame>
    <description>As measured by BCVA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of CME</measure>
    <time_frame>Assessed on Day -30 to -1 and Day 90 for change</time_frame>
    <description>As measured by OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need of additional steroids</measure>
    <time_frame>Assessed on Days 1, 7, 30, 90 for change</time_frame>
    <description>As measured by rescue medication added</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of rebound iritis</measure>
    <time_frame>Assessed on Days 1, 7, 30, 90 for change</time_frame>
    <description>As measured by presence of cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes</measure>
    <time_frame>Assessed on Day 90</time_frame>
    <description>As measured by patient questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Post-Surgical Ocular Pain</condition>
  <condition>Post-Surgical Ocular Inflammation</condition>
  <arm_group>
    <arm_group_label>DEXTENZA placed within the upper canaliculus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dextenza placed within the upper canaliculus following bilateral cataract extraction surgery with posterior chamber intraocular lenses implantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEXTENZA placed within the lower canaliculus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dextenza placed within the lower canaliculus following bilateral cataract extraction surgery with posterior chamber intraocular lenses implantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextenza 0.4Mg Ophthalmic Insert</intervention_name>
    <description>Dextenza 0.4Mg Ophthalmic Insert</description>
    <arm_group_label>DEXTENZA placed within the lower canaliculus</arm_group_label>
    <arm_group_label>DEXTENZA placed within the upper canaliculus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Been diagnosed with clinically significant cataract and CE/PCIOL has been planned&#xD;
&#xD;
          -  Bilateral cataract surgery with IOL has been planned&#xD;
&#xD;
          -  Willing and able to comply with clinic visits and study related procedures&#xD;
&#xD;
          -  Willing and able to sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy (must be ruled out in women of child-bearing age with pregnancy test)&#xD;
&#xD;
          -  Active infectious systemic disease&#xD;
&#xD;
          -  Active infectious ocular or extraocular disease&#xD;
&#xD;
          -  Obstructed nasolacrimal duct in the study eye(s)&#xD;
&#xD;
          -  Hypersensitivity to dexamethasone&#xD;
&#xD;
          -  Patients being treated with immunomodulating agents in the study eye(s)&#xD;
&#xD;
          -  History of prior ocular surgery, excluding Lasik or PRK&#xD;
&#xD;
          -  History of ocular inflammation or macular edema&#xD;
&#xD;
          -  Use of any systemic NSAIDs greater than 375 mg per day&#xD;
&#xD;
          -  Patients being treated with immunosuppressants and/or oral steroids&#xD;
&#xD;
          -  Patients with a corticosteroid implant (i.e. Ozurdex)&#xD;
&#xD;
          -  Patients with severe disease that warrants critical attention, deemed unsafe for the&#xD;
             study by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerry Assil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assil Eye Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kellie Burch</last_name>
    <phone>310-651-2392</phone>
    <email>kburch@assileye.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assil Eye Institute</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lindsay Harris</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kerry Assil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 2, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Assil Eye Institute</investigator_affiliation>
    <investigator_full_name>Kerry Assil, MD</investigator_full_name>
    <investigator_title>Sponsor-Investigator, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Dexamethasone</keyword>
  <keyword>Cataract</keyword>
  <keyword>Capsule Opacification</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Lens Diseases</keyword>
  <keyword>Eye Diseases</keyword>
  <keyword>Anti-Inflammatory Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

